Ther-O-02 - The COBALT-LYM study of CTX130: a phase 1 dose escalation study of CD70-targeted allogeneic CRISPR-Cas9–engineered CAR T cells in patients with relapsed/refractory (R/R) T-cell malignancies.

Authors :: Zain, DR
Iyer, SP
Sica, RA
Ho, PJ
Hu, B
Prica, A
Weng, W-K
Kim, YH
Khodadoust, MS
Palomba, ML
Foss, FM
Tipton, K
Cullingford, EL
Horwitz, SM
Sharma, A
Source :: European Journal of Cancer. 2022 Supplement 1, Vol. 173, pS21-S21. 1p.
Publication Year :: 2022

Subjects :: *HOMOGRAFTS
*COBALT
*CELLS
*CRISPRS
*T-cell lymphoma
*CANCER patient medical care

Full Text Access

Tools